Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 12/20 | 0.47 |
| ▸ | ROCK1 known ✓ | Q13464 | 12/20 | 0.47 |
| ▸ | PRKCD known ✓ | Q05655 | 3/20 | 0.46 |
| ▸ | PRKD3 known ✓ | O94806 | 2/20 | 0.34 |
| ▸ | PRKCZ known ✓ | Q05513 | 2/20 | 0.34 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.34 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 0.34 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.34 |
| ▸ | PRKCH known ✓ | P24723 | 1/20 | 0.34 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.34 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.34 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 0.34 |
| ▸ | PRKD1 known ✓ | Q15139 | 1/20 | 0.34 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.33 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.33 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.33 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 2/20 | 0.46 |
| ▸ | MARK3 | P27448 | 2/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31537 | 0.98 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Bromide SCHEMBL28709695 | 0.97 | ROCK2 (0.46) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Iodide SCHEMBL28700199 | 0.97 | ROCK2 (0.46) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Sulfuric Acid SCHEMBL28657307 | 0.94 | ROCK2 (0.45) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Formic Acid SCHEMBL28686548 | 0.91 | ROCK2 (0.43) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL28481339 | 0.85 | ROCK2 (0.41) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL14990455 | 0.83 | ROCK2 (0.48) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL998049 | 0.82 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL28644536 | 0.82 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL12925684 | 0.82 | ROCK2 (0.50) | ROCK2ROCK1PRKCDPLK4MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113582926-B | Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof | 安徽有吉医药科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-111909088-B | Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by using BTC/Ph3PO chloro-system | 浙江工业大学 | 2022-03-01 | — | — | CN | claimed |
| CN-113582926-A | Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof | 安徽有吉医药科技有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-111909088-A | Utilizing BTC/Ph3Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by PO chloro system | 浙江工业大学 | 2020-11-10 | — | — | CN | claimed |
| CN-113582926-B | Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof | 安徽有吉医药科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-111909088-B | Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by using BTC/Ph3PO chloro-system | 浙江工业大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-113582926-A | Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof | 安徽有吉医药科技有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-111909088-A | Utilizing BTC/Ph3Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by PO chloro system | 浙江工业大学 | 2020-11-10 | — | — | CN | disclosed |
| US-9540344-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9045460-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2015-03-26 | — | — | US | disclosed |
| EP-2818463-A1 | Production method of 1,4-diazepane derivatives | Kowa Co., Ltd. (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2610252-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | Kowa Co., Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-1852421-B1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7872136-B2 | Process for production of 4-fluoroisoquinoline-5-sulfonyl halide or salt thereof | KOWA CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090209765-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-1852421-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | Kowa Company, Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | ROCK2 59/4885ROCK1 95/4885PRKCD 2704/4885 |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | ROCK2 59/4885ROCK1 95/4885PRKCD 2704/4885 |
| US-20090209765-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | SALL4, STS, SFPQ | ROCK2 3563/4885ROCK1 4159/4885PRKCD 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.